{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T07:08:53Z","timestamp":1780643333555,"version":"3.54.1"},"reference-count":100,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017540","name":"National Heart Lung and Blood Institute Division of Intramural Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000861","name":"Burroughs Wellcome Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000861","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cardiovascular Medicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.tcm.2025.07.002","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T17:53:24Z","timestamp":1752602004000},"page":"530-538","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pushing the limits of LDL cholesterol: Emerging paradigms in cardiovascular risk reduction"],"prefix":"10.1016","volume":"35","author":[{"given":"Dadmehr","family":"Yaghoubi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer","family":"Sallam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.tcm.2025.07.002_bib0001","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.tcm.2025.07.002_bib0002","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1210\/edrv-3-3-299","article-title":"The role of lipoproteins in steroidogenesis and cholesterol metabolism in steroidogenic glands*","volume":"3","author":"Gwynne","year":"1982","journal-title":"Endocr Rev"},{"key":"10.1016\/j.tcm.2025.07.002_bib0003","unstructured":"Bile Acids: The Good, the Bad, and the Ugly - PubMed [Internet]. [cited 2024 Nov 2]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/11390813\/"},{"key":"10.1016\/j.tcm.2025.07.002_bib0004","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.chemphyslip.2016.05.003","article-title":"The role of cholesterol in membrane fusion","volume":"199","author":"Yang","year":"2016","journal-title":"Chem Phys Lipids"},{"issue":"4","key":"10.1016\/j.tcm.2025.07.002_bib0005","first-page":"343","article-title":"Low serum LDL cholesterol levels and the risk of fever, sepsis, and malignancy","volume":"37","author":"Shor","year":"2007","journal-title":"Ann Clin Lab Sci"},{"issue":"3","key":"10.1016\/j.tcm.2025.07.002_bib0006","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jcrc.2015.01.001","article-title":"Decreased serum level of lipoprotein cholesterol is a poor prognostic factor for patients with severe community-acquired pneumonia that required intensive care unit admission","volume":"30","author":"Chien","year":"2015","journal-title":"J Crit Care"},{"issue":"1","key":"10.1016\/j.tcm.2025.07.002_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(97)00161-5","article-title":"Nikolaj Nikolajewitsch Anitschkow (1885\u20131964) established the cholesterol-fed rabbit as a model for atherosclerosis research","volume":"135","author":"Finking","year":"1997","journal-title":"Atherosclerosis"},{"issue":"9921","key":"10.1016\/j.tcm.2025.07.002_bib0008","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0140-6736(13)61752-3","article-title":"The Framingham Heart Study and the Epidemiology of cardiovascular diseases: a historical perspective","volume":"383","author":"Mahmood","year":"2013","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.tcm.2025.07.002_bib0009","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1016\/S0021-9258(19)42341-7","article-title":"Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia","volume":"249","author":"Goldstein","year":"1974","journal-title":"J Biol Chem"},{"issue":"31","key":"10.1016\/j.tcm.2025.07.002_bib0010","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/S0021-9258(19)47763-6","article-title":"30 Years of cholesterol metabolism: the work of Michael Brown and Joseph Goldstein","volume":"281","author":"Kresge","year":"2006","journal-title":"J Biol Chem"},{"issue":"8934","key":"10.1016\/j.tcm.2025.07.002_bib0011","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"The Lancet"},{"issue":"25_Part_B","key":"10.1016\/j.tcm.2025.07.002_bib0012","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults","volume":"63","author":"Stone","year":"2014","journal-title":"JACC"},{"issue":"22","key":"10.1016\/j.tcm.2025.07.002_bib0013","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1093\/eurheartj\/ehaa1080","article-title":"How low is safe? The frontier of very low (<30 mg\/dL) LDL cholesterol","volume":"42","author":"Karagiannis","year":"2021","journal-title":"Eur Heart J"},{"issue":"suppl_1","key":"10.1016\/j.tcm.2025.07.002_bib0014","first-page":"A401","article-title":"Abstract 401: relative population percentiles of LDL cholesterol, non-HDL cholesterol and total cholesterol to HDL cholesterol ratio: the very large database of lipids study (VLDL-2)","volume":"33","author":"Elshazly","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"10.1016\/j.tcm.2025.07.002_bib0015","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2022.12567","article-title":"Trends in lipid concentrations and lipid control among US adults, 2007-2018","volume":"328","author":"Aggarwal","year":"2022","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.tcm.2025.07.002_bib0016","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0002-9149(02)02221-X","article-title":"Adult treatment panel II versus adult treatment panel III: what has changed and why?","volume":"89","author":"Pasternak","year":"2002","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.tcm.2025.07.002_bib0017","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jacc.2014.06.1159","article-title":"2013 ACC\/AHA guideline recommends fixed-dose strategies instead of targeted goals to lower blood cholesterol","volume":"64","author":"Smith","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2025.07.002_bib0018","unstructured":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines | Circulation [Internet]. [cited 2025 Mar 4]. Available from: https:\/\/www.ahajournals.org\/doi\/10.1161\/cir.0000000000000625"},{"issue":"14","key":"10.1016\/j.tcm.2025.07.002_bib0019","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk","volume":"80","author":"Lloyd -Jones Donald","year":"2022","journal-title":"JACC"},{"key":"10.1016\/j.tcm.2025.07.002_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2025.01.018","article-title":"Acute coronary syndromes guideline-at-a-glance","author":"Kumbhani","year":"2025","journal-title":"JACC"},{"issue":"1","key":"10.1016\/j.tcm.2025.07.002_bib0021","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"Supplement_1","key":"10.1016\/j.tcm.2025.07.002_bib0022","first-page":"S179","article-title":"Cardiovascular Disease and Risk Management: standards of Care in diabetes\u20142024","volume":"47","year":"2023","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.tcm.2025.07.002_bib0023","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.eprac.2023.02.001","article-title":"American Association of Clinical Endocrinology Consensus Statement: comprehensive type 2 diabetes management Algorithm \u20132023 update","volume":"29","author":"Samson","year":"2023","journal-title":"Endocr Pract"},{"issue":"6","key":"10.1016\/j.tcm.2025.07.002_bib0024","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1172\/JCI113013","article-title":"Heterogeneity of cholesterol homeostasis in man. Response to changes in dietary fat quality and cholesterol quantity","volume":"79","author":"McNamara","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1016\/j.tcm.2025.07.002_bib0025","article-title":"Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase - ENDO - 1977","year":"2024","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.tcm.2025.07.002_bib0026","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0065-2571(89)90063-0","article-title":"Biochemical aspect of HMG CoA reductase inhibitors","volume":"28","author":"Endo","year":"1989","journal-title":"Adv Enzyme Regul"},{"issue":"24","key":"10.1016\/j.tcm.2025.07.002_bib0027","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of blood cholesterol","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"9326","key":"10.1016\/j.tcm.2025.07.002_bib0028","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"10.1016\/j.tcm.2025.07.002_bib0029","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after Statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.tcm.2025.07.002_bib0030","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.tcm.2025.07.002_bib0031","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/1573403X13666170426104611","article-title":"The anti-inflammatory effects of statins on coronary artery disease: an updated review of the literature","volume":"13","author":"Diamantis","year":"2017","journal-title":"Curr Cardiol Rev"},{"issue":"17","key":"10.1016\/j.tcm.2025.07.002_bib0032","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2025.07.002_bib0033","unstructured":"Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis | Cardiology | JAMA | JAMA Network [Internet]. [cited 2024 Nov 4]. Available from: https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/646699"},{"issue":"9841","key":"10.1016\/j.tcm.2025.07.002_bib0034","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","article-title":"Cardiovascular benefits and diabetes risks of statin therapy in primary prevention","volume":"380","author":"Ridker","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.tcm.2025.07.002_bib0035","unstructured":"The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1) | PNAS [Internet]. [cited 2024 Nov 4]. Available from: https:\/\/www.pnas.org\/doi\/abs\/10.1073\/pnas.0500269102"},{"issue":"25","key":"10.1016\/j.tcm.2025.07.002_bib0036","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to Statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.tcm.2025.07.002_bib0037","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.jacc.2021.08.011","article-title":"Baseline low-density lipoprotein cholesterol and clinical outcomes of combining Ezetimibe with Statin Therapy in IMPROVE-IT","volume":"78","author":"Oyama","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.tcm.2025.07.002_bib0038","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc Natl Acad Sci"},{"issue":"12","key":"10.1016\/j.tcm.2025.07.002_bib0039","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.tcm.2025.07.002_bib0040","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jacc.2018.04.054","article-title":"The evolving future of PCSK9 inhibitors","volume":"72","author":"Rosenson","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.tcm.2025.07.002_bib0041","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of Alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.tcm.2025.07.002_bib0042","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.tcm.2025.07.002_bib0043","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1007\/s12325-022-02130-4","article-title":"Cost-effectiveness analysis of Evolocumab in adult patients with atherosclerotic cardiovascular disease in Canada","volume":"39","author":"Gr\u00e9goire","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.tcm.2025.07.002_bib0044","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2147\/VHRM.S338424","article-title":"Inclisiran: a new strategy for LDL-C lowering and prevention of atherosclerotic cardiovascular disease","volume":"19","author":"Albosta","year":"2023","journal-title":"Vasc Health Risk Manag"},{"issue":"16","key":"10.1016\/j.tcm.2025.07.002_bib0045","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.tcm.2025.07.002_bib0046","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11883-024-01199-2","article-title":"Oral PCSK9 inhibitors","volume":"26","author":"Agarwala","year":"2024","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.tcm.2025.07.002_bib0047","unstructured":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis | Nature Communications [Internet]. [cited 2024 Dec 22]. Available from: https:\/\/www.nature.com\/articles\/ncomms13457"},{"issue":"15","key":"10.1016\/j.tcm.2025.07.002_bib0048","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.tcm.2025.07.002_bib0049","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.tcm.2025.07.002_bib0050","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","article-title":"Evinacumab in patients with refractory hypercholesterolemia","volume":"383","author":"Rosenson","year":"2020","journal-title":"N Engl J Med"},{"issue":"42","key":"10.1016\/j.tcm.2025.07.002_bib0051","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1093\/eurheartj\/ehad547","article-title":"Significance of lipids, lipoproteins, and apolipoproteins during the first 14\u201316 months of life","volume":"44","author":"Taageby","year":"2023","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.tcm.2025.07.002_bib0052","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jacl.2021.07.003","article-title":"Monogenic and polygenic causes of low and extremely low LDL-C levels in patients referred to specialty lipid clinics: genetics of low LDL-C","volume":"15","author":"Jakubowski","year":"2021","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.tcm.2025.07.002_bib0053","unstructured":"Current Opinion in Lipidology [Internet]. [cited 2025 Mar 14]. Available from: https:\/\/journals.lww.com\/co-lipidology\/fulltext\/2014\/06000\/Hypobetalipoproteinemia_and_abetalipoproteinemia.3.aspx"},{"issue":"2","key":"10.1016\/j.tcm.2025.07.002_bib0054","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/MOL.0000000000000663","article-title":"Hypobetalipoproteinemia and abetalipoproteinemia: liver disease and cardiovascular disease","volume":"31","author":"Welty","year":"2020","journal-title":"Curr Opin Lipidol"},{"issue":"12","key":"10.1016\/j.tcm.2025.07.002_bib0055","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1194\/jlr.P039875","article-title":"Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis","volume":"54","author":"Minicocci","year":"2013","journal-title":"J Lipid Res"},{"key":"10.1016\/j.tcm.2025.07.002_bib0056","series-title":"GeneReviews\u00ae [Internet]","article-title":"Familial Combined hypolipidemia","author":"Burnett","year":"1993"},{"issue":"1","key":"10.1016\/j.tcm.2025.07.002_bib0057","doi-asserted-by":"crossref","first-page":"9208","DOI":"10.1038\/s41598-020-66027-4","article-title":"In-depth mendelian randomization analysis of causal factors for coronary artery disease","volume":"10","author":"Tan","year":"2020","journal-title":"Sci Rep"},{"issue":"25","key":"10.1016\/j.tcm.2025.07.002_bib0058","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a mendelian randomization analysis","volume":"60","author":"Ference","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2025.07.002_bib0059","unstructured":"Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes | New England Journal of Medicine [Internet]. [cited 2024 Nov 4]. Available from: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1410489?casa_token=U0F0PYibXHUAAAAA%3AUgsnwqSmPnfKgOYK7X4SUfhujGa7gjuGeDB-BZQkqGwvyb0V3CHxDPA_9vfxcmWy9tLtk0X91sdbO782"},{"issue":"22","key":"10.1016\/j.tcm.2025.07.002_bib0060","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"10106","key":"10.1016\/j.tcm.2025.07.002_bib0061","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"The Lancet"},{"issue":"15","key":"10.1016\/j.tcm.2025.07.002_bib0062","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","article-title":"Long-term Evolocumab in patients with established atherosclerotic cardiovascular disease","volume":"146","author":"O\u2019Donoghue","year":"2022","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.tcm.2025.07.002_bib0063","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1001\/jamacardio.2018.2258","article-title":"Efficacy and safety of further lowering of low-density lipoprotein cholesterol in patients starting with very low levels: a meta-analysis","volume":"3","author":"Sabatine","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"21","key":"10.1016\/j.tcm.2025.07.002_bib0064","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1161\/CIRCULATIONAHA.121.056536","article-title":"Cardiovascular benefit of lowering LDL cholesterol below 40 mg\/dl","volume":"144","author":"Marston","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2025.07.002_bib0065","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.124.072756","article-title":"Intensive lowering of LDL cholesterol levels with evolocumab in autoimmune or inflammatory diseases: an analysis of the FOURIER trial","author":"Zimerman","year":"2025","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.tcm.2025.07.002_bib0066","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary AtherosclerosisA randomized controlled trial","volume":"291","author":"Nissen","year":"2004","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.tcm.2025.07.002_bib0067","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.jacc.2016.02.014","article-title":"Effect of Statin treatment on modifying plaque composition","volume":"67","author":"Park","year":"2016","journal-title":"JACC"},{"issue":"22","key":"10.1016\/j.tcm.2025.07.002_bib0068","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of Evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.tcm.2025.07.002_bib0069","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of Alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction","volume":"327","author":"R\u00e4ber","year":"2022","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.tcm.2025.07.002_bib0070","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/jnnp-2015-312736","article-title":"Serum cholesterol levels, HMG-CoA reductase inhibitors and the risk of intracerebral haemorrhage. The multicenter study on cerebral haemorrhage in Italy (MUCH-Italy)","volume":"87","author":"Pezzini","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"19","key":"10.1016\/j.tcm.2025.07.002_bib0071","doi-asserted-by":"crossref","first-page":"e2286","DOI":"10.1212\/WNL.0000000000007454","article-title":"Lipid levels and the risk of hemorrhagic stroke among women","volume":"92","author":"Rist","year":"2019","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.tcm.2025.07.002_bib0072","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1212\/WNL.0000000000007853","article-title":"Low-density lipoprotein cholesterol and risk of intracerebral hemorrhage","volume":"93","author":"Ma","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.tcm.2025.07.002_bib0073","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ana.25740","article-title":"Genetically elevated LDL associates with lower risk of intracerebral hemorrhage","volume":"88","author":"Falcone","year":"2020","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.tcm.2025.07.002_bib0074","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41591-019-0366-x","article-title":"Causal associations of blood lipids with risk of ischemic stroke and intracerebral hemorrhage in Chinese adults","volume":"25","author":"Sun","year":"2019","journal-title":"Nat Med"},{"issue":"9753","key":"10.1016\/j.tcm.2025.07.002_bib0075","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.tcm.2025.07.002_bib0076","unstructured":"Treat Stroke to Target - American College of Cardiology [Internet]. [cited 2025 Mar 8]. Available from: https:\/\/www.acc.org\/Latest-in-Cardiology\/Clinical-Trials\/2019\/11\/15\/17\/51\/Treat-Stroke-to-Target"},{"key":"10.1016\/j.tcm.2025.07.002_bib0077","unstructured":"American College of Cardiology [Internet]. [cited 2025 Mar 8]. Stroke Prevention by Aggressive Reduction in Cholesterol Levels. Available from: https:\/\/www.acc.org\/latest-in-cardiology\/clinical-trials\/2010\/02\/23\/19\/21\/http%3a%2f%2fwww.acc.org%2flatest-in-cardiology%2fclinical-trials%2f2010%2f02%2f23%2f19%2f21%2fsparcl"},{"issue":"5","key":"10.1016\/j.tcm.2025.07.002_bib0078","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1161\/STROKEAHA.119.027759","article-title":"Stroke prevention with the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) inhibitor evolocumab added to statin in high-risk patients with stable atherosclerosis","volume":"51","author":"Giugliano","year":"2020","journal-title":"Stroke"},{"key":"10.1016\/j.tcm.2025.07.002_bib0079","unstructured":"American College of Cardiology [Internet]. [cited 2025 Mar 8]. Evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with Alirocumab. Available from: https:\/\/www.acc.org\/latest-in-cardiology\/clinical-trials\/2018\/03\/09\/08\/02\/http%3a%2f%2fwww.acc.org%2flatest-in-cardiology%2fclinical-trials%2f2018%2f03%2f09%2f08%2f02%2fodyssey-outcomes"},{"issue":"4","key":"10.1016\/j.tcm.2025.07.002_bib0080","article-title":"Lipid-lowering therapy and risk of hemorrhagic stroke: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"B\u00e9trisey","year":"2024","journal-title":"J Am Heart Assoc Cardiovasc Cerebrovasc Dis"},{"key":"10.1016\/j.tcm.2025.07.002_bib0081","unstructured":"Statins for the primary prevention of cardiovascular disease - Taylor, F - 2011 | Cochrane Library [Internet]. [cited 2025 Mar 8]. Available from: https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD004816.pub4\/abstract"},{"issue":"6","key":"10.1016\/j.tcm.2025.07.002_bib0082","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/17474930241239523","article-title":"Association of LDL-cholesterol <1.8\u2009mmol\/L and statin use with the recurrence of intracerebral hemorrhage","volume":"19","author":"Lee","year":"2024","journal-title":"Int J Stroke Off J Int Stroke Soc"},{"issue":"7","key":"10.1016\/j.tcm.2025.07.002_bib0083","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0002-9343(00)00353-3","article-title":"Effects of lovastatin on cognitive function and psychological well-being\u2217","volume":"108","author":"Muldoon","year":"2000","journal-title":"Am J Med"},{"issue":"11","key":"10.1016\/j.tcm.2025.07.002_bib0084","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.amjmed.2004.07.041","article-title":"Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults","volume":"117","author":"Muldoon","year":"2004","journal-title":"Am J Med"},{"issue":"7","key":"10.1016\/j.tcm.2025.07.002_bib0085","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1701131","article-title":"Cognitive function in a randomized trial of Evolocumab","volume":"377","author":"Giugliano","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.tcm.2025.07.002_bib0086","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400112","article-title":"Long-term cognitive safety of achieving very low LDL cholesterol with Evolocumab","volume":"4","author":"Zimerman","year":"2025","journal-title":"NEJM Evid."},{"issue":"5","key":"10.1016\/j.tcm.2025.07.002_bib0087","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jacc.2016.11.037","article-title":"Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials","volume":"69","author":"Robinson","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.tcm.2025.07.002_bib0088","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1161\/ATV.0000000000000164","article-title":"Aggressive LDL-C lowering and the brain: impact on risk for dementia and hemorrhagic stroke: a scientific statement from the American Heart Association","volume":"43","author":"Goldstein","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"10.1016\/j.tcm.2025.07.002_bib0089","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/CIRCRESAHA.115.307071","article-title":"Effects of Evolocumab on vitamin E and steroid hormone levels","volume":"117","author":"Blom","year":"2015","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.tcm.2025.07.002_bib0090","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/0026-0495(92)90143-X","article-title":"Long-term therapy with high-dose simvastatin does not affect adrenocortical and gonadal hormones in hypercholesterolemic patients","volume":"41","author":"Azzarito","year":"1992","journal-title":"Metabolism"},{"issue":"4","key":"10.1016\/j.tcm.2025.07.002_bib0091","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/bcpt.12169","article-title":"The effect of aggressive rosuvastatin treatment on steroid hormone production in men with coronary artery disease","volume":"114","author":"Krysiak","year":"2014","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"21","key":"10.1016\/j.tcm.2025.07.002_bib0092","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","article-title":"Cholesterol lowering in intermediate-risk persons without cardiovascular disease","volume":"374","author":"Yusuf","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.tcm.2025.07.002_bib0093","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jacc.2016.11.037","article-title":"Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials","volume":"69","author":"Robinson","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.tcm.2025.07.002_bib0094","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jacl.2018.02.002","article-title":"Effect of cholesterol lowering with statins or proprotein convertase subtilisin\/kexin type 9 antibodies on cataracts: a meta-analysis","volume":"12","author":"Dobrzynski","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.tcm.2025.07.002_bib0095","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jacl.2016.09.002","article-title":"Longitudinal treatment patterns among US patients with atherosclerotic cardiovascular disease or familial hypercholesterolemia initiating lipid-lowering pharmacotherapy","volume":"10","author":"Burke","year":"2016","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.tcm.2025.07.002_bib0096","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41569-023-00972-1","article-title":"Improving medication adherence in cardiovascular disease","volume":"21","author":"Nelson","year":"2024","journal-title":"Nat Rev Cardiol"},{"issue":"9","key":"10.1016\/j.tcm.2025.07.002_bib0097","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.amjmed.2011.12.013","article-title":"Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients","volume":"125","author":"Naderi","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.tcm.2025.07.002_bib0098","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ahj.2024.06.012","article-title":"Achievement of LDL-C <55 mg\/dL among US adults: findings from the cvMOBIUS2 registry","volume":"279","author":"Navar","year":"2025","journal-title":"Am Heart J"},{"issue":"15","key":"10.1016\/j.tcm.2025.07.002_bib0099","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/eurjpc\/zwae170","article-title":"Strike early-strike strong lipid-lowering strategy with proprotein convertase subtilisin\/kexin type 9 inhibitors in acute coronary syndrome patients: real-world evidence from the AT-TARGET-IT registry","volume":"31","author":"Gargiulo","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.tcm.2025.07.002_bib0100","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03533-w","article-title":"Endothelial cell-related genetic variants identify LDL cholesterol-sensitive individuals who derive greater benefit from aggressive lipid lowering","author":"Marston","year":"2025","journal-title":"Nat Med"}],"container-title":["Trends in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173825000945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173825000945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T03:57:30Z","timestamp":1777175850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1050173825000945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":100,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1050173825000945"],"URL":"https:\/\/doi.org\/10.1016\/j.tcm.2025.07.002","relation":{},"ISSN":["1050-1738"],"issn-type":[{"value":"1050-1738","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pushing the limits of LDL cholesterol: Emerging paradigms in cardiovascular risk reduction","name":"articletitle","label":"Article Title"},{"value":"Trends in Cardiovascular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tcm.2025.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}